Zymergen Inc. (ZY) Stock Analysis
DELISTED 2022
What happened to Zymergen Inc. (ZY) stock?
Zymergen Inc. (ZY) no longer trades on public markets. It was delisted in October 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zymergen Inc. (ZY) trades at $2.43. Zymergen Inc. specializes in the design, development, and commercialization of microbes, molecules, and materials, serving industries like electronics and agriculture. Sector: Basic materials.
Last analyzed: Mar 17, 2026Analyst Coverage for ZY: ZY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZY against Basic Materials peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ZY: 1/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Zymergen Inc. (ZY) Materials & Commodity Exposure
Zymergen Inc., a subsidiary of Ginkgo Bioworks, focuses on developing and commercializing innovative microbes, molecules, and materials. The company serves diverse sectors, including electronics, packaging, and agriculture, utilizing automation solutions to enhance its research and development processes within the specialty chemicals industry.
What Is the Investment Thesis for ZY?
Zymergen Inc., now a subsidiary of Ginkgo Bioworks, presents a unique investment proposition within the specialty chemicals sector. While its standalone financials, such as a negative profit margin of -2160.8% and a gross margin of -316.4%, indicate past challenges, the integration with Ginkgo provides potential synergies and access to advanced resources. Key value drivers include Zymergen's expertise in microbial engineering and automation, which can enhance Ginkgo's overall capabilities. Growth catalysts involve leveraging Ginkgo's platform to accelerate product development and commercialization. However, potential risks include integration challenges and the need to demonstrate tangible financial improvements post-acquisition. Investors should monitor the combined entity's ability to generate revenue and achieve profitability in the long term.
Based on FMP financials and quantitative analysis
ZY Key Highlights
Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc. since October 19, 2022.
- The company specializes in designing, developing, and commercializing microbes, molecules, and materials.
- Zymergen serves diverse industries, including electronics, packaging, healthcare, and agriculture.
- The company offers an automation solution comprising reconfigurable automation carts and cloud-based control software.
- Zymergen's financial performance shows a negative profit margin of -2160.8% and a gross margin of -316.4%.
Who Are ZY's Competitors?
ZY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACNT Ascent Industries Co. | $15.35 | +1.52% | $139M | 36 |
| CINR Sisecam Resources LP | $20.31 | -0.15% | $402M | 48 |
| EVA Enviva Inc. | $0.42 | +0.00% | $31.3M | 45 |
| GRFX Graphex Group Limited | $0.96 | +4.78% | $402M | 41 |
| LIN Linde plc | $480.38 | -0.16% | $222B | 51 |
| SHW The Sherwin-Williams Company | $353.59 | +2.41% | $85.8B | 72 |
| ECL Ecolab Inc. | $285.62 | +2.01% | $80.4B | 67 |
| GVDNY Givaudan S.A. | $80.07 | +3.09% | $37.0B | 53 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZY's Key Strengths?
Innovative microbial engineering platform
- Expertise in automation solutions for R&D
- Access to Ginkgo Bioworks' resources and expertise
- Potential for developing sustainable materials
What Are ZY's Weaknesses?
Negative profit and gross margins
- Reliance on Ginkgo Bioworks for resources
- Challenges in scaling operations and commercializing products
- Limited brand recognition as a subsidiary
What Could Drive ZY Stock Higher?
Integration with Ginkgo Bioworks to leverage synergies and resources.
- Potential product launches in sustainable materials and agriculture sectors.
- Development of advanced automation solutions for R&D labs.
- Expansion into high-performance materials for electronics.
What Are the Key Risks for ZY?
Integration challenges with Ginkgo Bioworks.
- Competition from established chemical companies.
- Regulatory hurdles for bio-based products.
- Economic downturn affecting R&D spending.
What Are the Growth Opportunities for ZY?
- Leveraging Ginkgo Bioworks' Platform: Zymergen can leverage Ginkgo Bioworks' extensive platform and resources to accelerate its research and development efforts. This includes access to Ginkgo's vast library of biological components, advanced automation capabilities, and expertise in strain engineering. By integrating its capabilities with Ginkgo's platform, Zymergen can potentially develop and commercialize new products more efficiently, targeting a larger share of the specialty chemicals market. This synergy can drive growth and enhance Zymergen's competitive position within the industry, with potential revenue impacts visible within the next 2-3 years.
- Expanding into Sustainable Materials: The increasing demand for sustainable and bio-based materials presents a significant growth opportunity for Zymergen. By focusing on developing eco-friendly alternatives to traditional chemicals and materials, Zymergen can cater to environmentally conscious consumers and industries. This includes developing biodegradable polymers, bio-based adhesives, and sustainable coatings. The market for sustainable materials is projected to grow significantly in the coming years, driven by regulatory pressures and consumer preferences, offering Zymergen a substantial growth avenue. Expect to see initial market traction within the next 1-2 years.
- Penetrating the Agriculture Sector: Zymergen can expand its presence in the agriculture sector by developing microbial solutions for crop protection and yield enhancement. This includes developing bio-based pesticides, fertilizers, and soil amendments that improve crop health and productivity. The agriculture sector is increasingly adopting sustainable practices, creating a demand for innovative microbial solutions. Zymergen's expertise in microbial engineering positions it to develop effective and environmentally friendly products for this market, potentially leading to increased revenue and market share. This expansion could yield results in the next 3-5 years.
- Developing Advanced Automation Solutions: Zymergen can further develop and commercialize its automation solutions for research and development labs. This includes offering customized automation systems, modular hardware building blocks, and cloud-based control software. The demand for automation in labs is growing, driven by the need for increased efficiency, accuracy, and throughput. By providing advanced automation solutions, Zymergen can cater to this demand and generate revenue from both product sales and service offerings. This growth opportunity can be realized within the next 2 years.
- Creating High-Performance Materials for Electronics: Zymergen can focus on developing high-performance materials for the electronics industry, such as advanced polymers, adhesives, and coatings. These materials can be used in various electronic devices, including smartphones, tablets, and computers. The electronics industry is constantly seeking innovative materials with enhanced properties, creating a demand for Zymergen's expertise. By developing specialized materials for this sector, Zymergen can capture a share of the high-value electronics market, with potential revenue streams emerging in the next 3-4 years.
What Are ZY's Competitive Advantages?
- Proprietary microbial engineering platform
- Expertise in automation solutions
- Access to Ginkgo Bioworks' resources
- Specialized knowledge in material science
What Does ZY Do?
Zymergen Inc., established in 2013 and based in Emeryville, California, is a company focused on designing, developing, and commercializing microbes, molecules, and materials. Its core business revolves around creating innovative solutions for various industries, including electronics, packaging, healthcare, and agriculture. Zymergen provides an automation solution that includes reconfigurable automation carts, modular hardware building blocks for customized lab work cells, and cloud-based automation control software. This integrated approach enables efficient and tailored automation systems for its clients. Zymergen's founding vision was to leverage synthetic biology and automation to create novel materials and chemicals with enhanced properties and functionalities. The company aimed to disrupt traditional manufacturing processes by offering sustainable and high-performance alternatives. However, Zymergen faced challenges in scaling its operations and commercializing its products, leading to its acquisition by Ginkgo Bioworks Holdings, Inc. in October 2022. As a subsidiary of Ginkgo Bioworks, Zymergen continues to operate, focusing on its core competencies in microbial engineering and automation. The acquisition has provided Zymergen with access to Ginkgo's broader platform and resources, potentially accelerating its research and development efforts. The company's commitment to serving diverse industries remains unchanged, as it strives to deliver innovative and sustainable solutions to meet evolving market demands.
What Products and Services Does ZY Offer?
- Designs and develops microbes, molecules, and materials.
- Commercializes its developed products for various industries.
- Offers automation solutions for research and development labs.
- Provides reconfigurable automation carts for customized lab setups.
- Develops modular hardware building blocks for work cell assembly.
- Offers cloud-based software to control integrated automation systems.
How Does ZY Make Money?
- Develops and sells microbes, molecules, and materials.
- Provides automation solutions to research labs.
- Generates revenue through product sales and service offerings.
What Industry Does ZY Operate In?
Zymergen Inc. operates within the specialty chemicals industry, a sector characterized by high innovation and customized solutions. The industry is driven by the demand for advanced materials and chemicals with specific properties, catering to diverse applications across various sectors. Key trends include the increasing adoption of sustainable and bio-based materials, driven by environmental concerns and regulatory pressures. The competitive landscape includes established chemical companies and emerging biotech firms. Zymergen's focus on microbial engineering and automation positions it to capitalize on the growing demand for sustainable and high-performance materials, particularly within Ginkgo Bioworks' broader ecosystem.
Who Are ZY's Key Customers?
- Electronics manufacturers
- Packaging companies
- Healthcare providers
- Agricultural businesses
Company Profile
Zymergen Inc. operates in the Chemicals - Specialty industry within the Basic Materials sector. It is headquartered in EmeryVille, US. The company is led by CEO Joshua J. Hoffmann. ZY has traded publicly since 2021.
Key Financial Metrics
Return on equity for Zymergen Inc. stands at 215.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -69.3%, showing how much profit it generates from its asset base. A current ratio of 5.54 indicates the company holds enough short-term assets to cover its near-term obligations.
ZY Financials
Bull Case vs Bear Case
Bull Case
- Zymergen's recent restructuring might signal a leaner, more focused operation. Remember when GE streamlined its divisions? Could be a similar play for efficiency.
- The company's pivot towards specific high-value products could attract strategic partnerships. Think of how CRISPR companies partner for targeted therapies.
- Despite challenges, the underlying technology still holds potential. It's like early-stage solar companies – initial struggles don't negate the long-term promise.
- Positive community sentiment around potential breakthroughs suggests renewed investor interest. It's similar to the buzz around mRNA tech before its COVID-19 breakthrough.
Bear Case
- Insider selling raises concerns about management's confidence in the company's future. It's reminiscent of Enron's executives selling before the collapse.
- Negative community sentiment regarding past performance creates a perception of unreliability. Like investors losing faith in Theranos despite initial hype.
- The company's history of missed targets and delays erodes investor trust. It mirrors the skepticism surrounding some biotech firms with repeated clinical trial setbacks.
- Market perception of Zymergen as a high-risk, high-reward play limits its appeal to risk-averse investors. Think of the volatile ride of meme stocks – exciting but unpredictable.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ZY Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · May 11, 2022
-
Earnings Scheduled For November 3, 2021
· Nov 3, 2021
Leadership: Joshua J. Hoffmann
CEO
Joshua J. Hoffmann serves as the CEO of Zymergen Inc. His background includes extensive experience in managing and leading technology-driven companies. He has a proven track record in driving innovation and commercializing new products. Hoffmann's expertise spans various industries, including biotechnology, materials science, and automation. He is known for his strategic vision and ability to build high-performing teams. His leadership is focused on leveraging Zymergen's core competencies to create value for its stakeholders.
Track Record: Under Joshua J. Hoffmann's leadership, Zymergen has focused on developing and commercializing innovative microbes, molecules, and materials. He has overseen the company's efforts to provide automation solutions for research and development labs. Key milestones include expanding Zymergen's presence in diverse industries and integrating its capabilities with Ginkgo Bioworks. His strategic decisions have aimed to enhance Zymergen's competitive position and drive long-term growth.
What Investors Ask About Zymergen Inc. (ZY) — Basic Materials
What happened to Zymergen Inc. (ZY) stock?
Zymergen Inc. (ZY) no longer trades on public markets. It was delisted in October 2022. The figures below are historical and are not a current quote.
Can I still buy ZY shares?
No. ZY stopped trading on public markets in October 2022, so the shares are not available through a broker. Anything you see quoted for ZY elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ZY stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Zymergen Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Zymergen Inc. do?
Zymergen Inc. specializes in the design, development, and commercialization of microbes, molecules, and materials. The company provides innovative solutions for various industries, including electronics, packaging, healthcare, and agriculture. Zymergen offers automation solutions for research and development labs, including reconfigurable automation carts and cloud-based control software. As a subsidiary of Ginkgo Bioworks, Zymergen leverages its expertise in microbial engineering and automation to create value for its stakeholders.
What do analysts say about ZY stock?
As Zymergen Inc. is now a subsidiary of Ginkgo Bioworks (ticker: DNA), standalone analyst ratings for ZY are no longer applicable. Investors should focus on the performance and prospects of Ginkgo Bioworks, considering Zymergen's contribution to the combined entity. Key valuation metrics for Ginkgo Bioworks include revenue growth, gross margin, and cash flow.
What are the main risks for ZY?
The main risks for Zymergen Inc. as a subsidiary of Ginkgo Bioworks include integration challenges, competition from established chemical companies, and regulatory hurdles for bio-based products. Integration risks involve the potential for disruptions and inefficiencies during the merging of Zymergen's operations with Ginkgo's platform.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial data may not reflect the most recent performance.